C
Cyclopharm Ltd
ASX:CYC
Cyclopharm Ltd
ASX:CYC
Price:
1.67 AUD
-1.76%
Market Closed
Updated:
May 14, 2024
P/S
Price to Sales
Price to Sales
5.7
Current
6.8
Median
2.4
Industry
Lower
than median
Higher
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=5.7
Market Cap
/
157.1m
Revenue
27.8m
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| AU |
C
|
Cyclopharm Ltd
ASX:CYC
|
157.1m AUD | 5.7 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
180.9B USD | 4.5 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
136.3B USD | 18.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
123.5B USD | 5.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
111.9B USD | 3.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
107.9B USD | 7.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
67.9B USD | 3.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
59.2B EUR | 2.7 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
375.2B CNY | 10.4 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
51.9B USD | 8.5 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
49.7B USD | 13.1 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
4.2
2-Years Forward
P/S
2.6
3-Years Forward
P/S
1.9
You don't have any saved screeners yet
